GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
LLY•Studies presented at Obesity Week 2026 linked GLP-1 use to heart improvements in patients with obesity and heart failure, lower healthcare use among Zepbound-treated patients, and fewer falls among older adults. The Zepbound analysis found 34% fewer hospitalizations and emergency visits at 12–18 months, but did not report whether savings offset drug costs.
1. Heart improvements
A Mayo Clinic study of patients with obesity and heart failure with reduced ejection fraction found greater improvements in left ventricular size, shape, structure and function after one year among the 146 patients taking GLP-1 drugs than among 237 matched controls. The medications were semaglutide, sold by Novo Nordisk as Wegovy and Ozempic, or tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro. Researchers said most improvements remained significant after accounting for weight changes; exploratory two-year analyses showed continued improvement in ejection fraction and heart size. A separate study of 81 adults with obesity and heart failure with preserved ejection fraction found semaglutide improved heart pressures and was associated with remission in more than half of treated patients after 52 weeks.
2. Zepbound and healthcare costs
Eli Lilly researchers compared more than 171,000 adults treated with Zepbound for weight management for at least a year with an equal number of similar untreated people; none had diabetes. Costs remained stable in the treated group and rose in the control group, while Zepbound-treated patients had 34% fewer hospitalizations and emergency department visits at 12–18 months. The researchers did not report patients’ medication costs or whether savings fully offset them.
3. Other reported findings
A study using data from about 15,000 US adults associated GLP-1 use with improvements in labor-force participation and productivity. Another study tracking more than 122,000 adults aged 65 and older with obesity found GLP-1 use was associated with a 13% lower risk of falls and a 37% lower risk of new wheelchair dependence; researchers said the study could not prove the drugs prevented either outcome.




